Hi [[ session.user.profile.firstName ]]

Cerebral Organoids as a 3D Model for Glioma

The prognosis of patients with glioblastoma (GBM) remains dismal with a median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a “normal” human microenvironment and the inability of many tumor cell lines to accurately reproduce GBM biology. To address these limitations, our guest presenter and her team have established a unique model system whereby they can retro-engineer patient-specific GBMs using patient-derived glioma stem cells (GSCs) and human embryonic stem cell (hESC)-derived cerebral organoids. Their cerebral organoid glioma (GLICO) model shows that GSCs home toward the human cerebral organoid, and deeply invade and proliferate within the host tissue forming tumors that closely phenocopy patient GBMs. Furthermore, cerebral organoid tumors form rapidly and are supported by an interconnected network of tumor microtubes that aids in the invasion of normal host tissue. This GLICO model provides a new system for modeling primary human GBM ex vivo and for high throughput drug screening.


Guest Presenter Bio:
Dr. Amanda Linkous previously served as the Director of the Starr Foundation Cerebral Organoid Translational Core at Weill Cornell Medicine (New York, NY). She completed her postdoctoral training in the Neuro-Oncology Branch at the National Cancer Institute (Bethesda, MD). Dr. Linkous is currently the Scientific Center Manager for the NCI's Center for Systems Biology of Small Cell Lung Cancer (SCLC) at Vanderbilt University, where she is developing similar 3D model systems to study the biology and refractory nature of SCLC (Nashville, TN)
Recorded Sep 26 2019 50 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Amanda Linkous, Ph.D.
Presentation preview: Cerebral Organoids as a 3D Model for Glioma

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • バイオ医薬研究・開発・製造における技術導入ポイントとアプリケーションの紹介 Nov 19 2019 6:00 am UTC 60 mins
    コーニングインターナショナル株式会社  ライサイエンス事業部 石渡 孝至
    大量培養容器とクローズドシステムソリューション
    ポリスチレン製マイクロキャリア法の紹介
    品質管理体制 (原料樹脂・溶出物・リーク・滅菌など)
    最新の培養事例紹介 (Vero・hMSC・HEK293Tなど)
  • Cerebral Organoids as a 3D Model for Glioma Recorded: Sep 26 2019 50 mins
    Amanda Linkous, Ph.D.
    The prognosis of patients with glioblastoma (GBM) remains dismal with a median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a “normal” human microenvironment and the inability of many tumor cell lines to accurately reproduce GBM biology. To address these limitations, our guest presenter and her team have established a unique model system whereby they can retro-engineer patient-specific GBMs using patient-derived glioma stem cells (GSCs) and human embryonic stem cell (hESC)-derived cerebral organoids. Their cerebral organoid glioma (GLICO) model shows that GSCs home toward the human cerebral organoid, and deeply invade and proliferate within the host tissue forming tumors that closely phenocopy patient GBMs. Furthermore, cerebral organoid tumors form rapidly and are supported by an interconnected network of tumor microtubes that aids in the invasion of normal host tissue. This GLICO model provides a new system for modeling primary human GBM ex vivo and for high throughput drug screening.


    Guest Presenter Bio:
    Dr. Amanda Linkous previously served as the Director of the Starr Foundation Cerebral Organoid Translational Core at Weill Cornell Medicine (New York, NY). She completed her postdoctoral training in the Neuro-Oncology Branch at the National Cancer Institute (Bethesda, MD). Dr. Linkous is currently the Scientific Center Manager for the NCI's Center for Systems Biology of Small Cell Lung Cancer (SCLC) at Vanderbilt University, where she is developing similar 3D model systems to study the biology and refractory nature of SCLC (Nashville, TN)
  • Corningシングルユース技術による細胞培養アプリケーションセミナー Recorded: Sep 3 2019 62 mins
    コーニングインターナショナル株式会社ライフサイエンス事業部 石渡孝至
    製品プロトコールを基に細胞培養事例の紹介と周辺装置を含めたプロセスソリューションについて概説します。
  • Cell Culture Fundamentals Recorded: Aug 15 2019 44 mins
    Kyung-A (Katie) Song, Ph.D.
    Cell culture is a fundamental technique for a variety of applications. Cells are cultured in controlled conditions including temperature, gas exchange, pH, and culture media (energy and nutrients). This webinar will introduce basic concepts of cell culture and provide tips on how to succeed in culturing mammalian cells.

    In this webinar, we will review:
    •Introduction to cell culture
    •Critical factors for successful cell culture
    •Cell culture tips and techniques

    Presenter Bio:

    Dr. Kyung-A Song graduated from Sungkyunkwan University with a Ph.D. in molecular biology and cancer immunology. She completed her postdoctoral fellowship in pharmaceutical research and drug discovery at Virginia Commonwealth University. She has extensive experience in a variety of cell culture techniques including isolation and culture of primary patient cells. She has worked with xenograft models and many cancer cell lines, and she has expertise in in vitro cell based functional assays and in vivo experiments. She is currently a Scientific Support Specialist for Corning Life Sciences where she answers customer inquiries about all products in the extensive Corning Life Sciences product portfolio.
  • Advanced Models for 3D Cancer Applications Recorded: May 22 2019 23 mins
    Audrey Bergeron, Applications Scientist
    In recent years, three-dimensional (3D) cell culture models have been emerging as the preferred in vitro cancer model as they better mimic the in vivo tumor microenvironment. For instance, 3D cultures develop hypoxic cores and demonstrate gradients of soluble factors and a diffusion profile for drugs similar to solid tumors. Understanding the interactions between cancer cells and other cell types in the tumor microenvironment is also critical to predicting therapeutic efficacy.

    In this webinar, Audrey Bergeron will review:
    •An introduction to 3D cell culture
    •Assay techniques in spheroid microplates
    •Several 3D cancer models and technology tools used to better capture the complexity of the tumor microenvironment in assay-compatible formats.

    About the Presenter:
    Audrey Bergeron is an applications scientist for Corning Life Sciences. She evaluates new products and develops protocols and technical documents using Corning cell culture products. She also provides product training to Corning employees and customers, and assists technical services with customer support by helping to troubleshoot customer experiments.
  • Corning®バイオプロセスの最新培養技術とシングルユース技術導入ポイントセミナー Recorded: Mar 13 2019 60 mins
    コーニングインターナショナル株式会社  ライサイエンス事業部 石渡 孝至
    バイオロジクスの大量培養を具現化に向け、幹細胞、癌細胞、タンパク発現系細胞の基礎的培養技術を示しながら、弊社のシングルユース品質規格(ISO / GMP / QMS)について概説します。

    <セミナーのポイント>
    細胞治療・遺伝子治療を中心にバイオプロセス開発が急速に進められております。幹細胞、癌細胞や標的タンパクを発現する細胞による再生医療・遺伝子治療を具現化する際に、最も大きな懸案事項となりますのが質、量そしてコストの問題があります。 そこでコーニングは、安全、安価かつ簡便な最新シングルユース技術についてレギュレーション、導入事例によるマーケットトレンドを示しながら、セルカルチャー(可溶性マイクロキャリア、撹拌・振盪容器、多段型培養容器)、閉鎖系チュービング(プレアッセンブル、無菌接続)、パッケージング(回収 / セルバンク)、データインテグリティ(バーコードによるトレーサビリティ管理)、品質規格(成型施設環境、BSE/TSE、発熱物質(Pyrogen)、USPクラスⅥ原料樹脂規格 / 滅菌保証レベル / エンドトキシン規格 / QC試験)および品質に関するドキュメンテーションサポート(バリデーションガイド)に関する情報を概説します。
  • Cell Culture Masterclass: A 10-Point Plan to Prevent Contamination Recorded: Jan 28 2019 44 mins
    Franziska Wienholz, Scientific Support Specialist, Corning Life Sciences
    Cell Culture Masterclass: A 10-Point Plan to Prevent Contamination

    All cell culture laboratories have experienced it: cell culture contamination and its inevitable loss of material. Contaminants may be biological or chemical, visible or invisible, destructive or seemingly benign, but in all cases, they adversely affect both the use of your cell cultures and the quality of your research.

    Identification and, even better, prevention of contamination are crucial for ensuring high-quality research. This expert webinar will present an overview on how to prevent, recognize and tackle contamination by introducing good lab practices and targeted interventions.

    If you work with cell culture daily or are interested in setting up prevention strategies to minimize contamination, then join SelectScience and Franziska Wienholz, scientific support specialist of Corning Life Sciences, for this educational masterclass. Franziska will share a 10-point plan to prevent contamination and provide a comprehensive refresher on all aspects of cell culture.

    Key learning objectives:

    Understand the basic rules of cell culture
    Know how to properly manage cell lines to prevent cross-contamination
    Be able to implement a 10-point plan to contamination prevention in your laboratory

    Who should attend:
    Scientists working with cell culture on a daily basis
    Cell culture managers who are interested in setting up programs to prevent contamination and determine authentication of cells
    Researchers that struggle with contamination issues
  • Advances in three-dimensional Cell Culture Recorded: Jan 28 2019 62 mins
    Dr. Richard E. Eglen, Vice President and General Manager, Corning Life Sciences.
    Advances in three-dimensional Cell Culture in Drug Research, Discovery and Biologic Manufacture.

    Cellular research is optimal when using physiologically relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and, increasingly, patient-specific cells in drug discovery. Over the past five years, technological improvements in 3D cell culture technology, to better mimic in vivo physiology, have also advanced. This is true not only in the areas of cancer and neurological research, but also in the assessment of clinical candidates for metabolic and toxicological liabilities. Furthermore, 3D cell culture is facilitating novel approaches to both the scale-up and manufacture of biologics, including those used in immuno- and stem cell-based therapies.

    Are you a scientist interested in 3D cell culture? Join this expert webinar, in which Dr. Richard Eglen will discuss the importance of 3D cell culture in drug discovery and manufacture and how technological improvements are causing significant advancements in this field.

    Learn about:

    - The existing and future impacts of 3D cell culture technology on fundamental research
    - The impacts of 3D cell culture on drug discovery and manufacture, particularly in the context of using phenotypically relevant cells?
    - The potential for spheroids, organoids, scaffolds, and hydrogels in cellular research and compound identification, screening, and development?
  • 3Dスフェロイド培養のアプリケーションとミニチュアライズ Recorded: Dec 20 2018 54 mins
    コーニングインターナショナル株式会社 ライフサイエンス事業部 江藤 哉子
    弊社独自の超低接着表面・形状のプレートを用いた三次元がんスフェロイドや、免疫細胞の作用モデルなどのハイスループットスクリーニング、オルガノイド作製の実例を交えて概説いたします。

    今回は、3Dスフェロイドを使用したアプリケーションをご検討中のみなさまに向けて、基礎から実際のアプリケーションまでをお話しいたします。
  • 多段型セルカルチャーおよびマイクロキャリアによる細胞培養技術セミナー Recorded: Nov 21 2018 61 mins
    コーニングインターナショナル株式会社  ライサイエンス事業部 石渡 孝至
    バイオロジクスの治験薬製造における効果的な細胞培養と分離工程の簡素化を実現させる幹細胞・癌細胞の基礎的培養技術を概説いたします。
    今回は、大量培養に向けたシングルユース技術導入のポイントを概説します。

    <セミナーのポイント>
    実際に静置型/撹拌型のシングルユース培養容器を使用した時のヒト間葉系幹細胞(hMSC)及びヒト胎児腎細胞(HEK293T)の培養データを例示します。
  • Short Tutorial: Techniques for Harvesting Adherent Cells Recorded: Jun 18 2018 5 mins
    Corning Life Sciences
    Harvesting your cells is an important step in maintaining healthy cultures. Good technique will lead to a healthy single cell suspension. There are many harvesting options depending on the cell line and application. In this video, we will discuss some tips/tricks to harvesting cells.
  • Short Tutorial: Corning® Matrigel® Matrix: Thin Coating Method Best Practices Recorded: Jun 4 2018 3 mins
    Corning Life Sciences
    Looking for tips using Matrigel matrix before you coat and plate your cells? We’ve got you covered. Watch our short tutorial for best practices on how to coat Matrigel Matrix as a thin gel layer.
    In search of more Matrigel matrix user information? We’ve summarized some other great tips and tricks for Matrigel in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • Short Tutorial: Corning® Matrigel® Matrix: Thin, Non-gelled Protein Layer Method Recorded: Jun 4 2018 3 mins
    Corning Life Sciences
    Trying to use Matrigel matrix for cell attachment? Watch our short video to learn the best way to coat Matrigel matrix in a thin, non-gelled protein layer.
    Interested in some more Matrigel matrix best practices? We’ve summarized some other great tips and tricks for Matrigel in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • Short Tutorial: Corning® Matrigel® Matrix: Thick Coat Method Best Practices Recorded: Jun 4 2018 3 mins
    Corning Life Sciences
    Did you know that cells can be cultured inside Matrigel matrix? Learn more about the “thick-coating” method to embed cells in a 3D, more in vivo-like environment.
    Looking for more great Matrigel Matrix tips and tricks? We’ve summarized a bunch in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • Short Tutorial: Corning® Matrigel® Matrix: Thawing Best Practices Recorded: Jun 1 2018 3 mins
    Corning Life Sciences
    We get a lot of questions on the best ways to thaw Matrigel matrix. Are the color changes normal? What are the best ways to ensure homogeneity? Get the answers to these questions and other best practices for effectively thawing the most widely used ECM in research, Corning Matrigel Matrix. We’ve summarized some other great tips and tricks for Matrigel in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • 最新技術 Corning®可溶性マイクロキャリアの培養システムを初公開 Recorded: May 29 2018 30 mins
    コーニングインターナショナル株式会社 ライフサイエンス事業部 石渡孝至
    シングルユース技術導入ポイントとなる効果的な細胞培養と分離工程の簡素化を実現するアプリケーションをMSC(間葉系幹細胞)を例に概説します。
  • 3D Imaging of 3D Cell Culture Models Recorded: May 17 2018 60 mins
    Tom Villani, Ph.D., Ann Rossi, Ph.D.
    One of the obstacles to working with 3D cell cultures is how to extract meaningful data from them. To address this problem, Visikol has developed their Visikol® HISTO-M™ tissue clearing reagent that allows for complete 3D cell culture characterization using confocal imaging or a 3-fold increase in cells detected using wide-field microscopy. This tissue clearing approach has been developed to be rapid and compatible with multi-well plates so that it can be conducted using automated pipetting robots and high content confocal imaging systems.
    By attending this webinar you will learn about:
    • Methods to enable 3D cell culture
    • Ways to enhance imaging and characterization of 3D spheroids

    Presenter Bios:
    Dr. Tom Villani is the CSO and Co-founder of Visikol Inc and is responsible for the companies scientific strategy. Since launching Visikol with Co-Founders Dr. Michael Johnson and Nick Crider, Dr. Villani has led the development of the Visikol HISTO tissue clearing technology for three-dimensional tissue imaging as well as a suite of digital pathology tools. Visikol has leveraged these technologies in its 3Screen service offering where the company is focused on transforming tissues into actionable insights as a service for primarily pharmaceutical companies.

    Dr. Ann Rossi graduated from the University of Rochester School of Medicine and Dentistry with a Ph.D. in Pharmacology and received postdoctoral training at the University of Chicago. Prior to joining Corning, Ann worked as a Senior Scientist at ARMGO Pharma, Inc., a small private pharmaceutical company, contributing her expertise in calcium signaling toward developing new assays for the company’s screening cascade. Ann is new to Corning Life Sciences as the Applications Lab Manager in Kennebunk, Maine and is drawing on her strong academic and industry research experience to direct the activities of the applications group.
  • OncoCilAir™: A 3D human in vitro model for lung cancer research Recorded: Nov 2 2017 38 mins
    Samuel Constant, PhD, Co-founder, CEO
    In this special webinar, our guest presenter Samuel Constant Ph.D., Co-founder, CEO for OncoTheis will review:

    - Novel in vitro tests for modelling lung cancer
    - A model that allows long term monitoring of toxicity or efficacy on respiratory tract
    - How OncoCilAir™ is a 3D human airway epithelium with tumors reconstituted in vitro

    Abstract:
    With more than 1 million deaths worldwide per year, lung cancer remains an area of unmet needs. Realistic human 3D models are required to improve preclinical predictivity. To that end, OncoTheis has engineered a novel in vitro lung cancer model, OncoCilAir™, which combines a functional reconstituted human airway epithelium, human lung fibroblasts and lung adenocarcinoma cell lines. Because of its unique lifespan (>3 month) and its dual composition (healthy and cancerous human tissues), OncoCilAir™ allows for the concurrent testing of the efficacy of drug candidates against malignant cells and their non-toxicity against healthy tissues. Accordingly, a first proof of concept study performed on a panel of anti-cancer drugs including the investigational drugs selumetinib and Mekinist® demonstrated that OncoCilAir™ carrying the KRASG12S mutation showed responsiveness in agreement with first clinical reported results, validating this unique tissue model as a predictive tool for anticancer drug efficacy evaluation. OncoTheis has now extended the model to EGFR mutations. Results showed that OncoCilAir™ EGFRdel19 is sensitive to Tarceva® and Iressa® treatments and provides a useful model to decipher in vitro mechanisms of resistance.
  • Modeling NAFLD and TGFβ-induced Fibrosis in 3D Bioprinted Human Liver Tissue Recorded: Oct 5 2017 52 mins
    Jeff Irelan, Ph.D.
    We hope you join us for this special webinar. Jeff Irelan, Director of Scientific Applications for Organovo will be our guest presenter.

    Abstract:
    Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder with an estimated prevalence of over 25% worldwide and is projected to become the leading indication for liver transplant by 2025. Despite decades of research focused on NAFLD, an effective treatment has yet to be approved. This is due in part to the reliance on cell culture and animal models that present challenges in translation due to limited functional longevity and species differences, respectively.

    ExVive™ 3D Bioprinted Human Liver Tissue, a clinically-translatable in vitro model, is ideal for studying the effects of drugs on liver disease progression, regression, and the mechanisms involved. Here, we present results showing a nutrient overload induction of liver disease and TGFβ-induced fibrosis in ExVive™ Human Liver Tissue. A variety of disease-relevant phenotypes including steatosis, inflammation, and fibrosis can be demonstrated in the model:
    •Nutrient overload leads to the accumulation of lipid droplets in hepatocytes.
    •Incorporation of Kupffer cells and stimulation induces inflammatory cytokine release.
    •Chronic exposure to nutrient overload leads to stellate cell activation and fibrosis.
    •Chronic exposure to chemical inducers of fibrosis or TGFβ stimulation leads to stellate cell activation and fibrosis.
    •A TGFβR1 kinase inhibitor effectively blocks TGFβ-induced fibrosis.

    Presenter Bio:
    Jeff Irelan holds a Ph.D. in molecular biology from the University of Oregon. As Director of Scientific Applications, Jeff interfaces with Organovo’s customers and R&D team to implement and expand the company’s portfolio of service offerings utilizing bioprinted tissue models.
  • New Technologies for Cellular Research: 3-Dimensional Cell Culture and Screening Recorded: Sep 22 2017 54 mins
    Richard M. Eglen, Ph.D
    It is now recognized that target and compound identification, as well as validation, are better conducted using cells with physiologically relevant phenotypes and genotypes. This assertion has accelerated the adoption of primary cells, stem cells, or patient-specific cells in cellular research, in general; and drug discovery, in particular.

    Technological improvements in three-dimensional (3D) cell culture technology, as a means to better mimic in vivo physiology, have accelerated recently—not only in the areas of cancer and neurological research, but also for the assessment of compound metabolic and toxicological liabilities. Furthermore, 3D cell culture can provide novel approaches to the scale-up and manufacture of biologically based medicines, including those used in immuno-and stem cell-based therapies.

    In this presentation, the existing and future impact of 3D cell culture technology on fundamental research, and drug discovery and manufacture will be addressed, particularly in the context of using phenotypically relevant cells. Specifically, it will discuss the potential for spheroids, organoids, scaffolds, and hydrogels in cellular research and compound identification, screening, and development.

    Future directions will also be covered, including organs-on-chips, hydrostatic flow technologies, microfluidics, and 3D bioprinting. Some of these approaches will allow for real-time observation of cellular responsiveness to novel compounds and drugs … boldly taking the researcher into a fourth dimension of 3D cell culture!
Training for Life Science Researchers
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Cerebral Organoids as a 3D Model for Glioma
  • Live at: Sep 26 2019 4:00 pm
  • Presented by: Amanda Linkous, Ph.D.
  • From:
Your email has been sent.
or close